To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
8,291 Current news from the industry pharmarss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
Company will focus on process development and improvements for manufacturing Baylor’s Covid-19 vaccine candidates
Merck and Baylor College of Medicine, Houston, Texas, USA, announced an extension of their ongoing collaboration to advance a manufacturing platform to fight Covid-19, designed to accelerate transition to Phase 1 clinical trials. “Vaccine manufacturing is extremely complicated, so we are ...
Acquisition is expected to accelerate the development of a COVID-19 vaccine candidate
Themis and MSD (trademark of Merck & Co., Inc.) announced that the companies have entered into a definitive agreement under which MSD, through a subsidiary, will acquire privately-held Themis. Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its ...
"Those who solve relevant problems will prevail"
Every year, HHL Leipzig Graduate School of Management and the auditing firm Ernst & Young (EY) hand out awards to young companies offering solutions for societal challenges through their products and services and creating public value. Some of the startups which received one of the coveted the ...
Strong capacity expansion by 30 percent from 2021
The Eppendorf Group is expanding its production capacity at the Oldenburg in Holstein site in Germany by building two additional production halls. As a result, Eppendorf Polymere GmbH, a wholly owned subsidiary ofEppendorf AG, will increase its total capacity by around 30 percent from 2021. A ...
First phase 1/2a clinical trial in healthy volunteers in June 2020 planned
CureVac AG announced positive pre-clinical results at a low dose for its lead vaccine candidate against the novel Coronavirus (SARS-CoV-2). The data showed a fast induction of a balanced immune response with high levels of virus neutralizing titers (VNTs) and T-cell responses. VNTs are a major ...
Even if men did not have prostate cancer could take androgen-deprivation therapies to prevent infection
Androgen-deprivation therapy could protect against infection with SARS-CoV-2 and against severe disease progression. This is suggested by a study led by a professor from the Università della Svizzera Italiana and ETH Zurich. Male cancer patients have a 1.8-fold increased risk of COVID-19 ...
Does the cost correspond to the particular drug’s effectiveness in combating the disease?
Do high prices of some cancer medicines have a higher benefit than those drugs with lower prices? An international UZH study has concluded that, in general, there is no correlation between costs of a cancer drugs and their clinical benefit. The researchers are therefore calling for the clinical ...
Antibodies were generated from convalescing COVID-19 patients
Evotec SE announced that its Seattle-based subsidiary Just – Evotec Biologics, Inc. has entered into a partnership with Ology Bioservices, Inc. (Ology Bio) for the evaluation and analytical characterisation of antibodies against SARS-CoV-2. This work falls under a contract awarded to Ology Bio by ...
Marinomed Biotech AG receives funding from the Austrian Research Promotion Agency (FFG) for the development of a SARS-CoV-2 therapy based on Carragelose®. The aim of the project is to clinically test an inhalation solution as an acute treatment for viral pneumonia caused by SARS-CoV-2 or other ...
Activities marked by COVID-19
The Bayer Group has registered a good start to 2020, with business activities in the first quarter greatly marked by the COVID-19 pandemic. “With our life science product portfolio in the areas of health and nutrition, we have shown our ability to successfully continue our business operations in ...